Exosc3 ablation compromises erythroid progenitor survival. (A) Experimental strategy. (B) Fetal liver live cell counts. Dead cells were excluded by trypan blue. (C) KIT+ BFU-E cell counts per E14.5 fetal liver. (D) BFU-E as percentage of lineage-depleted precursors (4 independent experiments: n = 33). (E) Representative flow cytometric plots for control Exosc3C/C Cre− and Exosc3C/C Cre+. (F) Percentage of BFU-E in live (AnnV−DRAQ7−), early apoptotic (AnnV+DRAQ7−), late apoptotic (AnnV+DRAQ7+), and dead (AnnV−DRAQ7+) cells, based on annexin V and DRAQ7 staining. Quantitative data are presented as box and whisker plots, with bounds from the 25th to 75th percentiles, the median line, and whiskers ranging from minimum to maximum values. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001, by Tukey multiple comparisons test. (G) Percentage of CFU-E in live, early apoptotic, late apoptotic, and dead cells (3 independent experiments: Exosc3C/C Cre− = 6, Exosc3C/WT Cre− =6, Exosc3C/WT Cre+ = 6, and Exosc3C/C Cre+ = 6).
